ARTICLE | Clinical News
Vedolizumab regulatory update
March 11, 2013 7:00 AM UTC
Takeda submitted an MAA to EMA for vedolizumab to treat moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD). The pharma said it plans to submit a BLA to FDA for the compound...